Lexicon Pharmaceuticals | LXRX - Les Intérêts Débiteurs Sur La Dette





Les Intérêts Débiteurs Sur La Dette Changement Date
Abbott USD 68M 26M 2026-03
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
Akebia Therapeutics 4.83M 359.32M 2025-12
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
AstraZeneca USD 484M 181M 2025-12
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Coherus Biosciences USD 2.25M 76K 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Esperion Therapeutics USD 22.64M 585K 2025-12
Halozyme Therapeutics USD 4.91M 615K 2025-12
Illumina USD 26M 1000K 2025-12
Insmed USD 20.6M 217K 2025-12
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
J&J USD 43M 25M 2026-03
Lexicon Pharmaceuticals USD 2.03M 124K 2025-12
MacroGenics USD 3.34M 2.54M 2025-09
MannKind USD 13.87M 6.54M 2025-12
Merck USD 479M 67M 2026-03
Moderna USD 11.49B 36B 2026-03
Novartis USD 343M 39M 2026-03
PTC Therapeutics USD 50.58M 2.59B 2025-12
Puma Biotechnology USD 3.37M 11K 2024-06
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Thermo Fisher Scientific USD 354M 11M 2026-03
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
United Therapeutics USD 3.1M 100K 2025-12
Vanda Pharmaceuticals 601.14M 23.61M 2025-09